in this press release may contain various forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995 ("PSLRA") and which may be based on or include assumptions concerning the operations, future results and prospects of KV Pharmaceutical company (the "Company"). Such statements may be identified by the use of words like "plan," "expect," "aim," "believe," "project," "anticipate," "commit," "intend," "estimate," "will," "should," "could" and other expressions that indicate future events and trends.
All statements that address expectations or projections about the future, including without limitation, product development, product launches, regulatory approvals, market position, acquisitions, revenues, expenditures, resumption of manufacturing and distribution of products and the impact of the recall and suspension of shipments on revenues, and other financial results, are forward-looking statements.
All forward-looking statements are based on current expectations and are subject to risk and uncertainties. In connection with the "safe harbor" provisions, the Company provides the following cautionary statements identifying important economic, political and technological factors, which among others, could cause actual results or events to differ materially from those set forth or implied by the forward-looking statements and related assumptions.
Such factors include (but are not limited to) the following: (1) changes in the current and future business environment, including interest rates and capital and consumer spending; (2) the difficulty of predicting FDA approvals, including timing, and that any period of exclusivity may not be realized; (3) acceptance and demand for new pharmaceutical products; (4) the introduction and impact of competitive products and pricing, including as a result of so-called authorized-generic drugs; (5) new product development and laun
Page: 1 2 3 4 5 6 Related medicine news :1
|SOURCE KV Pharmaceutical Company|
Copyright©2009 PR Newswire.
All rights reserved
. Jazz Pharmaceuticals to Present Data From First Phase III Study of Sodium Oxybate in Patients With Fibromyalgia2
. Quark Pharmaceuticals Announces the Presentation of Data Indicating Potential Utility of QPI-1002 in Chronic Kidney Disease at the RNA Interference Summit3
. Keryx Biopharmaceuticals, Inc. Receives Extension for Nasdaq Listing Compliance4
. Par Pharmaceutical Begins Shipment of Generic Miacalcin(R)5
. Raptor Pharmaceuticals to Collaborate with Roche on Therapeutic Delivery Across Blood-Brain Barrier6
. Metastorm Customer, Wyeth Pharmaceuticals, Wins CIO 100 Award for BPM Project7
. Endo Pharmaceuticals to Present at Goldman Sachs 30th Annual Healthcare Conference8
. Isis Pharmaceuticals to Present at Needhams 8th Annual Life Sciences Conference9
. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Needham Life Sciences Conference in New York on June 11, 200910
. Elsevier to Create New Guidelines for Pharmaceutical Article Reprint, Compilation and Custom Publications11
. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering